Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

96.830
-2.270-2.29%

Close Dec 18 16:00 ET

98.000
+1.170+1.21%

Post 20:01 ET

193.59BMarket Cap11.37P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top Gap Ups and Downs on Wednesday: CI, IBN, EA and More
Moomoo News18:00 ET · Markets
Express News | CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Benzinga14:45 ET
Express News | CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Benzinga11:08 ET
BioAge Stock Advances 14% On Novartis Research Collaboration
WSJDec 18 10:21 ET
BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
MT NewswiresDec 18 09:50 ET
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
GlobeNewswireDec 18 08:45 ET

Comments

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Asherboy88

Dec 11 08:09

$Novartis AG (NVS.US)$ what is happening ?? keeps going down

Movers and Shakers

Nov 21 07:11

Columns Today's Pre-Market Movers and Top Ratings | MSTR, NVDA, SNOW, PANW and More

Morning Movers
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $MicroStrategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...

Bitcoin retraces to 100K: An buying opportunity before trump's inauguration?

Heat List

Overall

No Data